Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs.
Banfor PN, Preusser LC, Campbell TJ, Marsh KC, Polakowski JS, Reinhart GA, Cox BF, Fryer RM. Banfor PN, et al. Among authors: fryer rm. Am J Physiol Heart Circ Physiol. 2008 Jan;294(1):H238-48. doi: 10.1152/ajpheart.01181.2007. Epub 2007 Nov 2. Am J Physiol Heart Circ Physiol. 2008. PMID: 17982006 Free article.
Evoked changes in cardiovascular function in rats by infusion of levosimendan, OR-1896 [(R)-N-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide], OR-1855 [(R)-6-(4-aminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one], dobutamine, and milrinone: comparative effects on peripheral resistance, cardiac output, dP/dt, pulse rate, and blood pressure.
Segreti JA, Marsh KC, Polakowski JS, Fryer RM. Segreti JA, et al. Among authors: fryer rm. J Pharmacol Exp Ther. 2008 Apr;325(1):331-40. doi: 10.1124/jpet.107.132530. Epub 2008 Jan 2. J Pharmacol Exp Ther. 2008. PMID: 18171907
(-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637), a novel ATP-sensitive potassium channel opener: hemodynamic comparison to ZD-6169, WAY-133537, and nifedipine in the anesthetized canine.
Fryer RM, Preusser LC, Calzadilla SV, Hu Y, Xu H, Marsh KC, Cox BF, Lin CT, Gopalakrishnan M, Reinhart GA. Fryer RM, et al. J Cardiovasc Pharmacol. 2004 Aug;44(2):137-47. doi: 10.1097/00005344-200408000-00001. J Cardiovasc Pharmacol. 2004. PMID: 15243293
Pharmacological characterization of the novel dihydropyridine potassium channel opener, (9R)-9-(3-iodo-4-methylphenyl)-5,9-dihydro-3H-furo[3,4-b]pyrano[4,3-e]pyridine-1,8(4H,7H)-dione (A-325100), and the regulation of cardiovascular function in conscious and anesthetized beagle dogs.
Fryer RM, Rakestraw PA, Preusser LC, Brune ME, Carroll WA, Buckner SA, Shieh CC, King LL, Marsh KC, Gopalakrishnan M, Cox BF, Reinhart GA. Fryer RM, et al. J Cardiovasc Pharmacol. 2005 Aug;46(2):232-40. doi: 10.1097/01.fjc.0000171755.28317.85. J Cardiovasc Pharmacol. 2005. PMID: 16044036
Effects of intravenous ABT-870 (iron (III)-hydroxide oligosaccharide) on mean arterial pressure and heart rate in the anaesthetized beagle: comparison with other iron-containing haematinic agents.
Preusser LC, Fryer RM, Gerhardt A, Hu Y, Delgado-Herrera L, Melnick JZ, Williams LA, Cox BF, Reinhart GA. Preusser LC, et al. Among authors: fryer rm. Clin Exp Pharmacol Physiol. 2005 Dec;32(12):1020-6. doi: 10.1111/j.1440-1681.2005.04299.x. Clin Exp Pharmacol Physiol. 2005. PMID: 16445566
Screening for cardiovascular safety: a structure-activity approach for guiding lead selection of melanin concentrating hormone receptor 1 antagonists.
Kym PR, Souers AJ, Campbell TJ, Lynch JK, Judd AS, Iyengar R, Vasudevan A, Gao J, Freeman JC, Wodka D, Mulhern M, Zhao G, Wagaw SH, Napier JJ, Brodjian S, Dayton BD, Reilly RM, Segreti JA, Fryer RM, Preusser LC, Reinhart GA, Hernandez L, Marsh KC, Sham HL, Collins CA, Polakowski JS. Kym PR, et al. Among authors: fryer rm. J Med Chem. 2006 Apr 6;49(7):2339-52. doi: 10.1021/jm0512286. J Med Chem. 2006. PMID: 16570930
63 results